中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
3期
107-109
,共3页
促性腺激素释放激素类似物%重组人生长激素%特发性中枢性性早熟%身高标准差分值
促性腺激素釋放激素類似物%重組人生長激素%特髮性中樞性性早熟%身高標準差分值
촉성선격소석방격소유사물%중조인생장격소%특발성중추성성조숙%신고표준차분치
Gonadotropin releasing hormone analogue%Recombinant human growth hormone%Idiopathic central preco-cious puberty%HtSDSBA
目的：探讨促性腺激素释放激素类似物(GnRHa)联合重组人生长激素(rhGH)治疗对特发性中枢性性早熟(ICPP)女童身高、骨龄发展的影响。方法将来本院就诊的60例ICPP女童作为研究对象,根据随机数字表法将患者分为单用组、联合组,每组各30例。单用组只给予GnRHa进行治疗,联合组在此基础上给予rhGH进行治疗,对比两组患儿的身高、骨龄变化情况。结果单用组、联合组治疗后预测成年身高的增加值分别为(3.93±1.01)、(7.77±1.95)cm,差异有统计学意义(t=5.3643,P=0.0008)；单用组、联合组患儿治疗后的HtSDSBA分别与治疗前比较,差异有统计学意义(t=6.1397,P=0.0007；t=9.7936,P=0.0003),联合组治疗后的HtSDSBA的差异值比单用组更明显(t=5.8396,P=0.0007)；联合组患儿的生长速度明显快于单用组(t=9.9873,P=0.0002)；两组患儿均未发现明显的不良反应。结论 GnRHa联合rhGH能明显改善ICPP女童的成年预测身高和HtSDSBA,对骨龄发展无明显影响,近期用药较安全。
目的：探討促性腺激素釋放激素類似物(GnRHa)聯閤重組人生長激素(rhGH)治療對特髮性中樞性性早熟(ICPP)女童身高、骨齡髮展的影響。方法將來本院就診的60例ICPP女童作為研究對象,根據隨機數字錶法將患者分為單用組、聯閤組,每組各30例。單用組隻給予GnRHa進行治療,聯閤組在此基礎上給予rhGH進行治療,對比兩組患兒的身高、骨齡變化情況。結果單用組、聯閤組治療後預測成年身高的增加值分彆為(3.93±1.01)、(7.77±1.95)cm,差異有統計學意義(t=5.3643,P=0.0008)；單用組、聯閤組患兒治療後的HtSDSBA分彆與治療前比較,差異有統計學意義(t=6.1397,P=0.0007；t=9.7936,P=0.0003),聯閤組治療後的HtSDSBA的差異值比單用組更明顯(t=5.8396,P=0.0007)；聯閤組患兒的生長速度明顯快于單用組(t=9.9873,P=0.0002)；兩組患兒均未髮現明顯的不良反應。結論 GnRHa聯閤rhGH能明顯改善ICPP女童的成年預測身高和HtSDSBA,對骨齡髮展無明顯影響,近期用藥較安全。
목적：탐토촉성선격소석방격소유사물(GnRHa)연합중조인생장격소(rhGH)치료대특발성중추성성조숙(ICPP)녀동신고、골령발전적영향。방법장래본원취진적60례ICPP녀동작위연구대상,근거수궤수자표법장환자분위단용조、연합조,매조각30례。단용조지급여GnRHa진행치료,연합조재차기출상급여rhGH진행치료,대비량조환인적신고、골령변화정황。결과단용조、연합조치료후예측성년신고적증가치분별위(3.93±1.01)、(7.77±1.95)cm,차이유통계학의의(t=5.3643,P=0.0008)；단용조、연합조환인치료후적HtSDSBA분별여치료전비교,차이유통계학의의(t=6.1397,P=0.0007；t=9.7936,P=0.0003),연합조치료후적HtSDSBA적차이치비단용조경명현(t=5.8396,P=0.0007)；연합조환인적생장속도명현쾌우단용조(t=9.9873,P=0.0002)；량조환인균미발현명현적불량반응。결론 GnRHa연합rhGH능명현개선ICPP녀동적성년예측신고화HtSDSBA,대골령발전무명현영향,근기용약교안전。
Objective To discuss the influence of the combined treatment of gonadotropin releasing hormone analogue (GnRHa) and recombinant human growth hormone (rhGH) on height and the development of bone age of idiopathic cen-tral precocious puberty (ICPP) in girls. Methods 60 girls with ICPP treated in our hospital were selected as the research object,and according to the random digital table method,they were divided into the single drug group and the combina-tion drug group,there were 30 cases in each group.The single drug group only was given GnRHa,while the combination drug group was given rhGH on the basis of the single drug group,height and change of bone age in the two groups were compared. Results In the single drug group and the combination drug group after treatment,prediction adult height was increased (3.93±1.01) cm and (7.77±1.95) cm respectively,and the difference was statistically significant (t=5.3643, P=0.0008);the single drug group and the combination drug group compared with those before treatment,HtSDSBA increased obviously (t=6.1397, P=0.0007;t=9.7936,P=0.0003);in the combination drug group,HtSDSBA increased more significantly than that in the single drug group (t=5.8396, P=0.0007);the growth speed of combination drug group was significantly faster than the single drug group (t=9.9873, P=0.0002);and there were no obvious adverse reaction in the two group. Conclusion GnRHa combined with rhGH can obviously improve the prediction adult height and HtSDSBA,and it had no significant effect on the development of bone age,recent medication is more safe.
